A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Inclusion Criteria: * Aged at least 18 years. * Documented evidence of NSCLC (stage IIIB/IV disease) * Disease progression or recurrence after both a platinum-based chemotherapy and at least 1 additional regimen for treatment of NSCLC * World Health Organisation (WHO) Performance Status of 0 or 1 * Estimated life expectancy of more than 12 weeks * Patient's tumour sample must be PD-L1 positive (≥25%of tumour cells with membrane staining (Cohort 1 and 2) or PD-L1 positive with ≥90% of tumour cells with membrane staining (Cohort 3)) Exclusion Criteria: * Prior exposure to any anti-PD-1 or anti-PD-L1 antibody * Brain metastases or spinal cord compression or unless asymptomatic, treated and stable (not requiring steroids). * Active or prior autoimmune disease or history of immunodeficiency * Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV. * Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris. * Any unresolved toxicity CTCAE \>Grade 2 from previous anti-cancer therapy. * Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \>Grade 1 * Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)